Scott A. Armstrong, MD, PhD

Chairman, Department of Pediatric Oncology
Associate Chief, Division Hematology/Oncology, Boston Children's Hospital
David G. Nathan Professor of Pediatrics, Harvard Medical School
Office Phone: 617-632-3644
Appointment Phone: 888-733-4662 (new); 617-632-3270 (established)
Fax: 617-632-4367
Preferred Contact Method: office phone

General

Treatment Centers
Disciplines
Pediatric Hematology/Oncology
Clinical Interests
Hematologic malignancies

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA  02215

Background

Board Certifications
Pediatric Hematology/Oncology, 2002
Fellowships
Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology, 2001
Residency
Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics, 1998
Internships
Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics, 1998
Medical School
University of Texas Southwestern Medical School, 1996
Biography

Scott A. Armstrong, MD, PhD, became the Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute in July 2016. He also serves as Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital.  He was previously the Director of the Center for Epigenetics Research at Memorial Sloan Kettering Cancer Center and Professor of Pediatrics at the Weill Cornell Medical College. Dr. Armstrong earned his medical degree and his PhD from University of Texas Southwestern Medical School in 1996. After internship and residency training with the Boston Combined Residency Program (BCRP) at Boston Medical Center and Boston Children’s Hospital, he completed a hematology/oncology fellowship at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. The major focus of his career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. His research program has focused on the mechanisms of leukemia development and the relationship between leukemia and normal hematopoietic stem cells.  He continues to direct a vigorous research program that focuses on development of new therapeutics that target chromatin based mechanisms, and he is actively involved in the development and translation of a number of new small molecule approaches that likely will be tested in clinical trials in the near future.

Appointments & Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Clinical Trials

Search our wide range of clinical trials, including novel therapies, immunotherapy and personalized therapy.callout bg

Harvard Medical Affiliate

HMS Callout FAD 

As a teaching affiliate of Harvard Medical School, our physicians are passing on their expertise to the next generation of pediatric hematologists and oncologists.